The Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction–associated steatotic hepatitis (MASH) is a chronic progressive liver disease that is highly prevalent worldwide. MASH is characterized by hepatic steatosis, inflammation, fibrosis, and liver damage, which eventually result in liver dysfunction due to cirrhosis or hepatocellular carcinoma. However, the cellular and molecular mechanisms underlying MASH progression remain largely unknown. Here, we found an increase of the Nr4a family of orphan nuclear receptor expression in intrahepatic T cells from mice with diet-induced MASH. Loss of Nr4a1 and Nr4a2 in T cell (dKO) ameliorated liver cell death and fibrosis, thereby mitigating liver dysfunction in MASH mice. dKO resulted in reduction of infiltrated macrophages and Th1/Th17 cells, whereas it led to a massive accumulation of Tregs in the liver of MASH mice. Combined single-cell RNA transcriptomic and TCR sequencing analysis revealed that intrahepatic dKO Tregs exhibited enhanced T cell immunoreceptor with Ig and ITIM domains (TIGIT) and IL-10 expression and were clonally expanded during MASH progression. Mechanistically, we found that dKO Tregs expressed high levels of basic leucine zipper ATF-like transcription factor (Batf), which promotes Treg cell proliferation and function upon TCR stimulation. Collectively, our findings not only provide an insight into the impact of intrahepatic Treg cells on MASH pathogenesis, but also suggest a therapeutic potential of targeting of the Nr4a family to treat the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, the role of hepatic Tregs in MASH has been explored only sparingly, and the limited studies available yield conflicting results, some implicating these cells in disease exacerbation, others attributing to them a protective, homeostatic function (18, 19).”
From Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“GSEA was performed using the Mouse MSigDB collection (68).”
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · cited 2×
“Seurat was used to analyze data (31).”
The single-cell transcriptional landscape of mammalian organogenesis
Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D. M., Hill, A. J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0969-x · Cited by 4,490 · cited 1×
“The analysis of differentiation trajectories was performed in Monocle3 using the SeuratWrapper package to convert the integrated Seurat object (69).”
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 2×
“MASH occurs in approximately 20% of patients with MASLD and is characterized by steatosis, persistent inflammation, liver damage, and fibrosis (2, 3).”
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 1×
“Despite intense clinical trials, currently there are no effective therapies for MASH (5), since the cellular and molecular mechanisms underlying MASH progression are not fully understood.”
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · cited 1×
“Indeed, the Treg_Foxp3 cluster had high expression of genes related to suppressive function of Tregs, such as Tig-it , Ctla4 , and Il10 , indicative of mature Tregs phenotype (45).”
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · cited 1×
“MASH occurs in approximately 20% of patients with MASLD and is characterized by steatosis, persistent inflammation, liver damage, and fibrosis (2, 3).”
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234 · cited 2×
“We found high expression of Areg , Il1rl1 , and Ikzf2 in the 1_1 cluster and these genes are feature of Tregs that function in tissue repair upon muscle injury (34).”
Cited by
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81
“Another study demonstrated that a massive accumulation of Tregs in the livers of MASH mice ameliorated liver cell death and fi brosis, thus mitigating liver dysfunction in MASH [77].”
Role of regulatory T cells in inflammatory liver diseases
Yang, L., & Zheng, S. G. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103806 · Cited by 19
Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17
Interactions between hepatic stellate cells and immune cells: Implications for liver fibrosis
Xie, D., Huang, Y., Yu, Y., Jin, W., Zhang, X., & Yu, F. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168062 · Cited by 13
Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD
Zhao, H., Wang, W., Zhu, P., & Shi, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680878 · Cited by 13
Regulatory T cells in cancer and inflammation
Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 12
“456,457 These con fl icting fi ndings re fl ect the dual roles of Tregs in NASH — both in promoting fi brosis and inhibiting in fl ammation.”
Interacting roles of gut microbiota and T cells in the development of autoimmune hepatitis
Wu, Q., Ge, Z., Lv, C., & He, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584001 · Cited by 9
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 6
“This loss of immune tolerance allows for the uncontrolled activation of autoreactive T cells that target stressed or injured hepatocytes, creating a feed-forward loop of inflammation and cell death [74, 75].”
Alsharif, O., & Rombouts, K. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00037-9 · Cited by 3
Lee, S. E., Jo, M. G., Park, S. W., Kim, H. J., Yun, S. P., & Kim, J.-W. (2026) · Animal Cells and Systems · doi:10.1080/19768354.2026.2630463 · Cited by 2
“In a diet-induced MASH model, intra-hepatic T cells showed increased Nr4a expression, and T cell–specific deletion of Nr4a1 and Nr4a2 resulted in attenuated MASH pathology accompanied by increased hepatic Treg accumulation (Aki et al. 2024; Hayatsu et al. 2017).”
Regulatory T cells safeguard liver health during metabolic-associated steatohepatitis
Hanna, B. S., Langston, P. K., Marin-Rodero, M., Ramirez, R. N., Wan, M., Benoist, C., & Mathis, D. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536314123 · Cited by 1
“Our results align with studies showing that ablation of Nr4a1 and Nr4a2 in T cells enhanced liver Treg accumulation and attenuated MASH pathology (19), but contrast with claims of a detrimental role for Tregs in MASH (18, 28).”
Lin, Y., & Wang, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117906 · Cited by 1
Zhou, Z., Liu, L., Zhou, Y., Yan, Y., Wang, B., Lv, X., Qin, J., Liu, Z., Liu, Y., Meng, Z., et al. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111676
The biliary tree: A new frontier in mucosal immunology?
Guo, Y., Chouik, Y., Hao, Y., Kohlhepp, M. S., & Guillot, A. (2026) · Mucosal Immunology · doi:10.1016/j.mucimm.2026.04.006
Wang, Y., & Lin, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118110
Depletion of NAT10 in T cells attenuates metabolic dysfunction–associated steatohepatitis in mice
Yang, Y., Lu, J., Ma, M., Zhou, J., Wang, E., Lu, Y., Dai, Z., Zhou, B., & Li, Y. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000973
“[30] In standard medium, Nat10 transcription was rapidly downregulated within 1 hour following stimulation, followed by an increase at 16 hours.”
Wang, X., Wang, X., Zhao, L., & Song, L. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02250-z
“Overexpression of NR4A2 and KLF4 is associated with pro-inflammatory effects in NAFLD [ 57, 58].”
GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential
Gan, X., Zhang, L., Yu, T., Jin, S., Wu, Y., Xu, R., Zhang, Y., Zhang, J., Xu, L., & Wang, X. (2026) · Biomolecules · doi:10.3390/biom16071060
“For example, the intrahepatic Treg subset described by Aki et al. suppresses the pro-inflammatory responses of Th1 and Th17 cells, thereby reducing the activation of profibrotic pathways and attenuating fibrosis [190].”
Mu, Y., Zhu, W., Wei, Z., Guo, Z., Chen, H., Cheng, Y., & Zhou, W. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02991-4
“Multi-omics studies have further revealed complex interactions among hepatocytes and immune cell populations during MASLD progression, providing a more integrated understanding of the hepatic microenvironment [14, 15].”
Ruting, W., Hongxi, W., Liang, J., Huiping, L., Zhenjin, H., Zhang, R., Zhang, R., Hongzhen, T., & Jiang, F. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120705
Zeng, X., Luo, P., Wu, C., Long, J., Zhang, S., Wang, Y., Teng, L., Zhang, H., Fan, D., Hu, Z., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103606
“Meanwhile, the inflammatory niche restricts T reg recruitment and impairs anti-inflammatory IL-10 secretion, ablating their capacity to constrain pro-fibrotic inflammation [36 – 38].”
Zhou, M., Huo, J., Wang, W., Lai, E., Han, B., & Zhang, T. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108471
Metadata
- Authors
- Aki, D., Hayakawa, T., Srirat, T., Shichino, S., Ito, M., Saitoh, S.-I., Mise-Omata, S., & Yoshimura, A.
- Affiliations
- Wakayama Medical University (JP)
- Keio University (JP)
- Tokyo University of Science (JP)
- Kyushu University (JP)
- Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
- Corresponding author
- Aki, Daisuke
- Venue
- Journal of Clinical Investigation
- Published
- 2024-10-15
- Volume
- 134
- Issue
- 23
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC11601941
- OpenAlex
- W4403424193
- Cited by
- 22
- References
- 69
- Citations by year
- 2026: 13 · 2025: 9
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- JSPS, SENSHIN Medical Research Foundation, Takeda Science Foundation, Keio Gijuku Academic Developmental Funds, AMED, Chemo-Sero-Therapeutic Research Institute, Uehara Memorial Foundation (23K06587,19K07629,21H05044,22K1944,23K06723,23H04785,21H02719,22H05064,JP23gm1110009,JP23zf0127003,22gm6210012,JP21gm6210025)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, orphan nuclear receptor, regulatory T cells, liver fibrosis, Treg proliferation, BATF, TIGIT, IL-10, hepatic macrophages, Th1/Th17 cells, hepatocyte death, T cell clonal expansion, therapeutic target
- MeSH terms
- Animals, Disease Models, Animal, Fatty Liver, Humans, Liver, Liver Cirrhosis, Male, Mice, Knockout, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Nuclear Receptor Subfamily 4, Group A, Member 1, Nuclear Receptor Subfamily 4, Group A, Member 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.